View Live: SenzaGen’s CEO at Financial Meetings Øresund

Live presentations at Financial Meetings Øresund’s event “Sverige fortsatt starkt för Life Science?”

SenzaGen’s CEO Anki Malmborg Hager will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not.

Watch live presentation here:

SenzaGen’s CEO to speak at Financial Meetings Øresund, in Lund November 19, 2018

SenzaGen’s CEO Anki Malmborg Hager will speak at Financial Meetings Øresund, November 19, 2018.

As a speakers in the event “Sverige fortsatt starkt för Life Science? Anki will share the inspiring story of SenzaGen and how SenzaGen’s platform GARD®, a group of tests for animal-free safety testing, can replace animal tests using genomics in test tubes to assess whether chemicals are allergenic or not.

For more information and registration,

SenzaGen hosts open webinars on Respiratory Sensitization on 4 and 5 December

In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARDtechnology platform

The presentations on 4 and 5 December 2018, will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics.  A thorough explanation of the GARD platform will be covered as well as its versatility and reliability for safety assessment applicable to all industries. Sensitization testing with GARD is based on functional genomics.

The presentation will cover:

  • Development of the genomic-based GARD test platform for skin sensitization hazard, potency classification, and now also respiratory sensitization.
  • Dendritic cells – why they are also relevant for respiratory sensitization.
  • Gene mapping – what genes are in the assay, and how are they relevant for sensitization.
  • How GARD can discriminate between skin and respiratory sensitization and why this is relevant.
  • Update on the development of the SenzaGen R&D pipeline including GARD for materials – testing medical devices, GARD for proteins – classification of protein sensitizers, GARD for mixtures – assessment of complex formulations and Unknown or Variable Composition UVCBs.

Next generation in vitro skin and respiratory sensitization testing using genomics with GARD

The GARD™ platform is a versatile in vitro testing strategy which currently consist of three assays targeting two toxicological endpoints: skin sensitization (GARDskin & GARDpotency) and respiratory sensitization (GARDair). These assays make use of unique genomic biomarker signatures comprising genes involved in pathways known to be immunologically relevant to the sensitization process. Supported by modern technologies for pattern recognition, the large informational content provided by this approach enable for mechanism-of-action based decisions, which becomes evident in a consistently high predictive accuracy

Don’t miss the opportunity to learn more from our researchers.

Register by clicking on any of the links below.


European Registration
Tue 4 Dec 2018, 15:00 CET

Americas Registration
Wed 5 Dec 2018, 13:00 EST


SenzaGen’s presentation at Unicorn Summit

On October 10, SenzaGen participated in the Vator Securities Unicorn Summit, a capital market day organized to bring together some of the most innovative and fast-growing Swedish life science companies with investors.
Anki Malmborg Hager presented Senzagen’s developments and accelerated efforts towards further strengthening the commercial organization and the global presence of GARD®, a group of tests for animal-free safety testing. You will find Anki’s full presentation here

SenzaGen presenterar vid Vator Securities Unicorn Summit 10 oktober 2018 from Vator Securities on Vimeo.

Anki Malmborg Hager interviewed by EFN (in Swedish)

On October 15, SenzaGen’s CEO Anki Malmborg Hager was interviewed by Swedish financial media EFN about SenzaGen’s cruelty-free test platform GARD®, our business model and new sales targets. The result was a short and to-the-point interview about our core business and our future. You will find the filmed interview (in Swedish) here:

GARDair – A novel assay for assessment of chemical respiratory sensitizers based on a genomic platform

Henrik Johansson, Andy Forreryd, Robin Gradin, Angelica Johansson, Olivia Larne, Emil Aaltonen, Anders Jerre, Carl A.K. Borrebaeck and Malin Lindstedt
SenzaGen AB, Lund, Sweden. Department of Immunotechnology, Lund, Sweden.

Exposure to chemicals may induce allergic hypersensitivity reactions in skin or respiratory tract. To minimize exposure, chemicals are routinely screened for their sensitizing potential. Proactive identification has historically been performed using animal models, but the use of animals for safety assessment of cosmetics was recently banned within EU. Today, similar trends are spreading both globally and across industry and market segments. Methods for specific identification of respiratory sensitizers are greatly underdeveloped, with no validated, or even widely used assay readily available. Thus, there is an urgent need for development of non-animal-based methods for hazard classification of respiratory sensitizing chemicals.

GARD– Genomic Allergen Rapid Detection – is a state of the art technology platform for assessment of chemical sensitizers (Figure 1). It is based on a dendritic cell (DC)-like cell line, thus mimicking the cell type involved in the initiation of the response leading to sensitization. Following test chemical exposure, induced transcriptional changes are measured to study the activation state of the cells. These changes are associated with the immunological decision-making role of DCs in vivo and constitutes of e.g. up-regulation of co-stimulatory molecules, induction of cellular and oxidative stress pathways and an altered phenotype associated with recognition of xenobiotic matter. By using state-of-the-art gene expression technologies, high informational content data is generated, that allows the user to get a holistic view of the cellular response induced by the test substance.

GARDair is a novel assay for assessment of respiratory sensitizers. It is an adaptation of the GARD platform, utilizing gene expression analysis of predictive biomarker signatures and state-of-the-art data analysis methodology. GARDair has been proven functional and is currently progressing towards industrial implementation and  regulatory acceptance with financial support from the EU programme Horizon 2020. This progress includes scientific verification of results, assay optimization, assay
transfer and formal validation by a blinded ring trial.

Link to poster

SenzaGen presenting at Vator Securities Unicorn Summit on October 10, 2018

SenzaGen will participate in the Vator Securities Unicorn Summit, which takes place today, October 10, at Medicon Village in Lund. Anki Malmborg Hager will present Senzagen´s developments and accelerated efforts towards further strengthening the commercial organization and the global presence of SenzaGen’s platform GARD®, a group of tests for animal-free safety testing.

Unicorn Summit is a capital market day organized by Vator Securities to bring together some of the most innovative and fast-growing Swedish life science companies with investors. More information about Vator Securities

SenzaGen to attend the Medicon Valley Inhalation Symposium 2018

SenzaGen will attend the 7th Medicon Valley Inhalation Symposium – Future Opportunities of Inhalation 2018, 3- 4 October at Medicon Village. A two-day symposium on New drugs, Inhalation devices, Dissolutions, Tox and Pre-Clinical testing and Regulatory updates. 

Dr Henrik Johansson will hold a presentation on Thursday, October 4 at 09:25, on the topic “Predictive Respiratory Toxicology with the GARD In-Vitro Testing Platform”. Come and get the latest updates, meet us and all the experts and stakeholders there!

GARD® and SenzaGen mentioned in Chemical Risk Manager, September 18, 2018

Don’t miss the interesting article in Chemical Risk Manager in Chemical Watch, written by Dr. Emma Davies, with the title; Skin sensitization integrated testing strategies need rethink, expert suggests.

Emma Davies is interviewing the UK academic Dr. David Roberts after his publication of an article in Regulatory Toxicology and Pharmacology in July where he is discussing the relevance of Integrated Testing Strategy (ITS) for skin sensitization testing as well as he is presenting data on the performance of the GARDskin test method compared to the OECD -tests.  

In short, David Roberts from Liverpool John Moores University questions the science behind integrated testing strategies (ITS) for combining in vitro test methods to predict skin sensitisation, as required by REACH. Instead, Roberts suggests, ”… that the genomic allergen rapid detection (GARD) assay for skin sensitisation may outperform other OECD validated test methods, either alone or in combination.”

Dr. David Roberts will present his data and the research behind the article at the EUSAAT meeting 23-26 September in Linz, and at the ESTIV conference 15-18 October in Berlin

Read the article here (requires subscription to Chemical Watch):



SenzaGen Logotype (Square) Color RGB.jpg

Inspelning samt transkript från telefonkonferens gällande ECVAMs utvärdering av GARDskin flyttad till våren 2019

Inspelning från telefonkonferens (19 september, 2018) gällande ECVAMs utvärdering av GARDskin flyttad till extra möte i den vetenskapliga kommittén under våren 2019, på svenska.

Recording from telephone conference (September 19, 2018) regarding ECVAM evaluation of GARDskin rescheduled to an extra scientific committee meeting in spring 2019, in Swedish.


Nedan finner du även transkript från telefonkonferensen, på svenska.

Below you will find a transcript from the telephone conference, in Swedish.